Core Viewpoint - Beihai Kangcheng-B (01228) has seen a significant increase in its stock price, rising over 12% recently and nearly 20 times year-to-date, indicating strong market interest and potential growth opportunities [1] Group 1: Stock Performance - As of the latest update, Beihai Kangcheng's stock price is reported at 2.77 HKD, with a trading volume of 50.08 million HKD [1] - The stock has experienced a year-to-date increase of nearly 2000% [1] Group 2: Strategic Partnerships - On August 13, Beihai Kangcheng announced a share subscription agreement with Baiyang Pharmaceutical, with Baiyang investing 100 million HKD in Beihai Kangcheng [1] - The partnership includes a commercial service agreement, allowing Baiyang's subsidiary to promote specific products from Beihai Kangcheng in mainland China, Hong Kong, and Macau [1] Group 3: Regulatory Developments - In 2025, the National Healthcare Security Administration will introduce a "Commercial Insurance Innovative Drug Directory," with application processes starting on July 11 [1] - Three of Beihai Kangcheng's products have passed the initial review as of August 12, which could expedite their market entry [1] - Inclusion in the Commercial Insurance Innovative Drug Directory would provide commercial insurance support for these drugs, potentially reducing the economic burden on patients and increasing product accessibility [1]

Group 1 - Beihai Kangcheng-B (01228) has seen a nearly 17% increase recently, with a year-to-date cumulative increase exceeding 1500% [1] - As of the report, the stock price is at 2.23 HKD, with a trading volume of 41.075 million HKD [1] - Beihai Kangcheng has entered into a share subscription agreement with Baiyang Pharmaceutical (301015), where Baiyang will subscribe for shares worth approximately 100 million HKD at a price of 1.34 HKD per share [1] Group 2 - The two companies have signed an exclusive commercialization service agreement to deepen strategic collaboration, allowing Baiyang's subsidiary to promote specific products of Beihai Kangcheng in mainland China, Hong Kong, and Macau [1] - On August 12, the National Healthcare Security Administration released the preliminary list of innovative drugs for commercial insurance, with three rare disease products from Beihai Kangcheng passing the review [1] - The approved products include: - Gorynin (injectable velaglucerase beta) for long-term enzyme replacement therapy for patients aged 12 and above with Type I and III Gaucher disease - Mairuibai (oral chloramphenicol) for treating ALGS/PFIC cholestatic pruritus - Haierisi (injectable idursulfase beta) for treating Mucopolysaccharidosis Type II [1]

Core Viewpoint - Beihai Kangcheng-B (01228) has seen a significant stock price increase, with a recent rise of nearly 9% and a current price of 2.09 HKD, reflecting a trading volume of 20.28 million HKD [1] Group 1: Product Approval and Market Impact - The National Healthcare Security Administration announced on August 12 that three rare disease products from Beihai Kangcheng have passed the preliminary review for the commercial insurance innovative drug directory [1] - The approved products include: - Goryning (injectable Velaglucerase beta) for treating type I and III Gaucher disease in adolescents and adults aged 12 and above, which was approved for market in May this year - Mirebai (oral Chlorambucil) for treating cholestatic pruritus associated with ALGS/PFIC - Haier Si (injectable Idursulfase beta) for treating Mucopolysaccharidosis type II [1] Group 2: Financing and Shareholding Changes - Beihai Kangcheng recently announced the issuance of 74.97 million new shares to Baiyang Pharmaceutical (301015) at a price of 1.34 HKD per share, representing a discount of 19.76% compared to the price before suspension [1] - The net proceeds from the subscription, approximately 98.66 million HKD, will be used for the research and development of commercialized products, marketing and promotional activities, loan repayment, and daily operations [1] - Following the completion of this transaction, Baiyang Pharmaceutical will hold 14.99% of Beihai Kangcheng's equity, and has stated that it has no intention to acquire any controlling stake in the company within the next three years [1]